The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy (Q38219225)

31 August 2017

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy (English)

1 reference

Katarina Sjögreen Gleisner

31 August 2017

0 references

Katarina Sjögreen Gleisner

6

0 references

Carlo Chiesa

Carlo Chiesa

3

0 references

Glenn D Flux

Glenn Flux

8

0 references

Lidia Strigari

Lidia Strigari

1

0 references

Manuel Bardies

Manuel Bardies

4

0 references

Michael Lassmann

Michael Lassmann

7

0 references

author name string

Mark Konijnenberg

2

1 reference

PubMed ID

24915892

31 August 2017

Yong Du

5

1 reference

31 August 2017

11 June 2014

1 reference

31 August 2017

13

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

31 August 2017

41

1 reference

31 August 2017

10

1 reference

31 August 2017

1976-1988

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-014-2824-5

31 August 2017

0 references

cites work

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Calculation of integrated biological response in brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of prec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Treatment of Graves' Hyperthyroidism with Radioiodine: Results of a Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Liver disease induced by radioembolization of liver tumors: description and possible risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

EANM procedure guidelines for therapy of benign thyroid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2824-5

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy

21 January 2018

1 reference

12 December 2020

Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer

1 reference

12 December 2020

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail

1 reference

12 December 2020

Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres

1 reference

12 December 2020

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method

1 reference

12 December 2020

Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.

1 reference

12 December 2020

Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.

1 reference

12 December 2020

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants

1 reference

12 December 2020

Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer

1 reference

12 December 2020

Dosimetry in nuclear medicine therapy: radiobiology application and results

1 reference

12 December 2020

Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.

1 reference

12 December 2020

Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan

1 reference

12 December 2020

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

1 reference

12 December 2020

Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass

1 reference

12 December 2020

The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma

1 reference

12 December 2020

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"

1 reference

12 December 2020

The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer

1 reference

12 December 2020

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

12 December 2020

Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy

1 reference

12 December 2020

Biological optimization of heterogeneous dose distributions in systemic radiotherapy

1 reference

12 December 2020

Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation

1 reference

12 December 2020

Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma

1 reference

12 December 2020

Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

1 reference

12 December 2020

A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism

1 reference

12 December 2020

A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease

1 reference

12 December 2020

Individualized dosimetry in the management of metastatic differentiated thyroid cancer

1 reference

12 December 2020

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

1 reference

12 December 2020

10.1007/S00259-014-2824-5

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24915892